계명대학교 의학도서관 Repository

Optimal Dose of Thymoglobulin for Induction Therapy in High Risk Kidney Transplant Recipients

Metadata Downloads
Author(s)
Yaerim KimSeong Sik KangWoo Yeong ParkKyubok JinSung Bae ParkUi Jun ParkHyoung Tae KimSeungyeup Han
Keimyung Author(s)
Kang, Seong SikPark, Woo YoungPark, Sung BaeJin, Kyu BokPark, Ui JunKim, Hyoung TaeHan, Seung Yeup
Department
Dept. of Internal Medicine (내과학)
Dept. of Surgery (외과학)
Kidney Institute (신장연구소)
Journal Title
대한이식학회지
Issued Date
2016
Volume
30
Issue
2
Keyword
Immunosuppressive agents(면역억제제)Kidney transplantation(신장이식)Thymoglobulin(치모글로불린)
Abstract
Background: Thymoglobulin has been used for induction therapy to prevent acute rejection and delayed graft function (DGF)
in kidney transplant patients. However, the usual dose of thymoglobulin is considered to be related with frequent infection. We
compared the efficacy and safety of low-dose thymoglobulin to high-dose treatment in high risk recipients with kidney
transplantation.
Methods: Twenty-one kidney transplant recipients underwent induction treatment with thymoglobulin and were divided into
two groups: patients treated with low-dose (<6.0 mg/kg) and high-dose thymoglobulin (≥6.0 mg/kg). All patients showed one
or more risk factors for acute rejection or DGF. The risk factors were re-transplantation, recipient or donor age over 60 years,
human leukocyte antigen full mismatch, and panel-reactive antibody more than 50%. We compared incidence of acute rejection,
infection, hematologic complications, and graft survival between two groups.
Results: The demographic characteristics of the two groups were comparable. Mean follow-up duration was 11.9±4.3 months,
and cumulative thymoglobulin dosage was 6.3±1.6 mg/kg. The incidence rates of acute antibody-mediated rejection (AMR), DGF
and infectious events as cytomegalovirus disease, or urinary tract infection were not significantly different between the two groups.
Neutropenia occurred more frequently in the high-dose thymoglobulin group, but there was no statistically significant difference.
The rate of graft loss were similar between the two groups.
Conclusions: There were no differences in graft survival, infectious disease, and hematologic problems between the two groups.
We suggest to lower the dose of thymoglobulin to less than 6 mg/kg for prevent acute AMR and DGF in high risk patients.
Keimyung Author(s)(Kor)
강성식
박우영
박성배
한승엽
진규복
박의준
김형태
Publisher
School of Medicine
Citation
Yaerim Kim et al. (2016). Optimal Dose of Thymoglobulin for Induction Therapy in High Risk Kidney Transplant Recipients. 대한이식학회지, 30(2), 82–85. doi: 10.4285/jkstn.2016.30.2.82
Type
Article
ISSN
1598-1711
DOI
10.4285/jkstn.2016.30.2.82
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33248
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
1. School of Medicine (의과대학) > Dept. of Surgery (외과학)
3. Research Institutues (연구소) > Kidney Institute (신장연구소)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.